RNA-based therapeutics, including antisense oligonucleotides, will revolutionize the standard of care for many diseases, including cancer and genetic disorders, and will open new avenues towards improved personalized medicine. The “RNAnoTher” laboratory work, directed by Dr. Palma Rocchi, focus on developing mRNA-based drugs in the context of castration-resistant prostate cancer (CRPC). Advanced prostate cancer (PC) develop